JP2016527221A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016527221A5 JP2016527221A5 JP2016526518A JP2016526518A JP2016527221A5 JP 2016527221 A5 JP2016527221 A5 JP 2016527221A5 JP 2016526518 A JP2016526518 A JP 2016526518A JP 2016526518 A JP2016526518 A JP 2016526518A JP 2016527221 A5 JP2016527221 A5 JP 2016527221A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- targeting moiety
- mutant
- beta
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306047.5 | 2013-07-19 | ||
| EP13306047 | 2013-07-19 | ||
| PCT/EP2014/064283 WO2015007542A1 (en) | 2013-07-19 | 2014-07-04 | Targeted modified il-1 family members |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016527221A JP2016527221A (ja) | 2016-09-08 |
| JP2016527221A5 true JP2016527221A5 (enExample) | 2017-08-10 |
| JP6475713B2 JP6475713B2 (ja) | 2019-02-27 |
Family
ID=48874235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016526518A Active JP6475713B2 (ja) | 2013-07-19 | 2014-07-04 | 標的修飾ｉｌ−１ファミリーメンバー |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US9932409B2 (enExample) |
| EP (1) | EP3022226B1 (enExample) |
| JP (1) | JP6475713B2 (enExample) |
| KR (1) | KR102275090B1 (enExample) |
| CN (1) | CN105612180B (enExample) |
| AU (1) | AU2014292377B2 (enExample) |
| BR (1) | BR112016001128A2 (enExample) |
| CA (1) | CA2918518C (enExample) |
| DK (1) | DK3022226T3 (enExample) |
| ES (1) | ES2714504T3 (enExample) |
| IL (1) | IL243466B (enExample) |
| MX (1) | MX370348B (enExample) |
| SG (1) | SG11201600167SA (enExample) |
| WO (1) | WO2015007542A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA43134A (fr) | 2015-10-30 | 2018-09-05 | Aleta Biotherapeutics Inc | Compositions et méthodes de transduction tumorale |
| WO2017075537A1 (en) | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
| EP3371311B1 (en) | 2015-11-06 | 2021-07-21 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
| US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
| CN109071632B (zh) | 2016-02-05 | 2022-12-30 | 奥里尼斯生物科学私人有限公司 | 靶向性治疗剂及其用途 |
| US11248057B2 (en) | 2016-03-07 | 2022-02-15 | Vib Vzw | CD20 binding single domain antibodies |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| WO2017194783A1 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Targeted mutant interferon-beta and uses thereof |
| EP3455245A2 (en) | 2016-05-13 | 2019-03-20 | Orionis Biosciences NV | Therapeutic targeting of non-cellular structures |
| CN110114368B (zh) | 2016-10-24 | 2024-08-02 | 奥睿尼斯生物科学私人有限公司 | 靶向突变干扰素-γ及其用途 |
| KR102642385B1 (ko) | 2017-02-06 | 2024-03-04 | 오리오니스 바이오사이언시스 엔브이 | 표적화된 키메라 단백질 및 이의 용도 |
| EP3576765B1 (en) | 2017-02-06 | 2025-07-16 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
| CA3050601A1 (en) | 2017-02-07 | 2018-08-16 | Vib Vzm | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CN110913954A (zh) * | 2017-03-03 | 2020-03-24 | 黑曜石疗法公司 | 免疫疗法的组合物和方法 |
| WO2018231827A1 (en) | 2017-06-12 | 2018-12-20 | Bluefin Biomedicine, Inc. | Anti-il1rap antibodies and antibody drug conjugates |
| EP3664829A4 (en) | 2017-08-09 | 2021-05-05 | Orionis Biosciences, Inc. | LIAISON OFFICERS AT PD-1 AND PD-L1 |
| CN117924493A (zh) | 2017-08-09 | 2024-04-26 | 奥里尼斯生物科学有限公司 | Clec9a结合剂及其用途 |
| EP3665201A4 (en) | 2017-08-09 | 2021-06-02 | Orionis Biosciences, Inc. | CD8 BINDERS |
| US11970537B2 (en) * | 2017-12-26 | 2024-04-30 | Nanjing GenScript Biotech Co., Ltd. | Fusion protein dimer using antibody Fc region as backbone and use thereof |
| US12655186B2 (en) | 2018-01-26 | 2026-06-16 | Orionis Biosciences, Inc. | Chimeric protein comprising anti-XCR1 antibody and modified interferon alpha 2 |
| CA3090406A1 (en) | 2018-02-05 | 2019-08-08 | Orionis Biosciences, Inc. | Fibroblast binding agents and use thereof |
| EP3833391A4 (en) | 2018-08-08 | 2022-08-10 | Orionis Biosciences, Inc. | ANTI-SIRP1ALPHA CHIMERIC PROTEINS AND USES THEREOF |
| EP3890773A4 (en) | 2018-11-08 | 2022-11-09 | Orionis Biosciences, Inc. | MODULATION OF DENDRITIC CELL LINES |
| WO2020198665A1 (en) | 2019-03-28 | 2020-10-01 | Orionis Biosciences, Inc. | Fibroblast activation protein binding agents and use thereof |
| CN113840833B (zh) | 2019-03-28 | 2025-06-17 | 奥里尼斯生物科学股份有限公司 | 基于clec9a的嵌合蛋白复合物 |
| JP7689079B2 (ja) | 2019-03-28 | 2025-06-05 | オリオニス バイオサイエンシズ，インコーポレイテッド | 治療用インターフェロンアルファ１タンパク質 |
| US12544426B2 (en) | 2019-06-19 | 2026-02-10 | Orionis Biosciences, Inc. | Combination therapy with CD13-targeted chimeric proteins or chimeric protein complexes |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| CA3185087A1 (en) * | 2020-07-07 | 2022-01-13 | Nikolai Kley | Immunostimulatory adjuvants |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0489116B1 (en) | 1989-08-22 | 1994-04-06 | Immunex Corporation | Fusion proteins comprising gm-csf and il-3 |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5914254A (en) * | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
| AU1215801A (en) * | 1999-10-21 | 2001-04-30 | Sarnoff Corporation | Bi-potential electrode space-saving cathode ray tube |
| EP1812038A1 (en) | 2004-11-18 | 2007-08-01 | VIB vzw | Fibronectin iii domain as leptin receptor antagonists |
| WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| US7947265B2 (en) | 2006-08-02 | 2011-05-24 | Mcgill University | Fusion proteins and methods for modulation of immune response |
| WO2008124086A2 (en) | 2007-04-05 | 2008-10-16 | President And Fellows Of Harvard College | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| WO2009003145A1 (en) * | 2007-06-26 | 2008-12-31 | University Of Miami | Antibody-endostatin fusion protein and its variants |
| ES2536772T3 (es) | 2007-09-21 | 2015-05-28 | The Regents Of The University Of California | El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales |
| US8334101B2 (en) | 2008-09-26 | 2012-12-18 | University Of Massachusetts | Intracellular DNA receptor |
| CA2749558C (en) | 2008-12-08 | 2019-01-15 | Complix Nv | Single-chain antiparallel coiled coil proteins |
| RU2583876C2 (ru) * | 2009-08-17 | 2016-05-10 | Роше Гликарт Аг | Иммуноконъюгаты направленного действия |
| CN102497885A (zh) * | 2009-09-10 | 2012-06-13 | 赛托斯生物技术公司 | 白介素-1β突变蛋白偶联物在糖尿病治疗中的用途 |
| WO2012170072A1 (en) | 2011-06-06 | 2012-12-13 | Immungene, Inc. | Engineered antibody-tnfsf member ligand fusion molecules |
| CN104203982B (zh) | 2011-10-28 | 2018-08-31 | 特瓦制药澳大利亚私人有限公司 | 多肽构建体及其用途 |
| WO2013107791A1 (en) | 2012-01-20 | 2013-07-25 | Vib Vzw | Targeted mutant alpha-helical bundle cytokines |
| PL2822575T3 (pl) | 2012-03-03 | 2020-08-10 | Immungene, Inc. | Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu |
-
2014
- 2014-07-04 CA CA2918518A patent/CA2918518C/en active Active
- 2014-07-04 BR BR112016001128-7A patent/BR112016001128A2/pt not_active Application Discontinuation
- 2014-07-04 US US14/905,352 patent/US9932409B2/en active Active
- 2014-07-04 SG SG11201600167SA patent/SG11201600167SA/en unknown
- 2014-07-04 ES ES14735574T patent/ES2714504T3/es active Active
- 2014-07-04 DK DK14735574.7T patent/DK3022226T3/en active
- 2014-07-04 MX MX2016000723A patent/MX370348B/es active IP Right Grant
- 2014-07-04 JP JP2016526518A patent/JP6475713B2/ja active Active
- 2014-07-04 EP EP14735574.7A patent/EP3022226B1/en active Active
- 2014-07-04 WO PCT/EP2014/064283 patent/WO2015007542A1/en not_active Ceased
- 2014-07-04 CN CN201480040652.6A patent/CN105612180B/zh active Active
- 2014-07-04 AU AU2014292377A patent/AU2014292377B2/en active Active
- 2014-07-04 KR KR1020167002679A patent/KR102275090B1/ko active Active
-
2016
- 2016-01-05 IL IL24346616A patent/IL243466B/en active IP Right Grant
-
2018
- 2018-02-21 US US15/901,545 patent/US20180186894A1/en not_active Abandoned
-
2019
- 2019-03-21 US US16/360,793 patent/US20190202934A1/en not_active Abandoned
-
2020
- 2020-04-28 US US16/860,660 patent/US20200255545A1/en not_active Abandoned
-
2023
- 2023-02-01 US US18/163,026 patent/US20230235086A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016529232A5 (enExample) | ||
| MX2020013062A (es) | Anticuerpos anti proteina relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticoides (gitr) y sus metodos de uso. | |
| WO2014145159A3 (en) | Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use | |
| EP4276114A3 (en) | Cd20 binding single domain antibodies | |
| CY1124456T1 (el) | Antισωματα αντι-5τ4 και συζευγματα φαρμακου αντισωματων | |
| EP4183806A3 (en) | Glycan-interacting compounds and methods of use | |
| MX370348B (es) | Miembros de la familia il-1 modificados dirigidos. | |
| WO2012149412A3 (en) | Anti-endoglin (cd105) antibodies, immunoconjugates, and uses thereof | |
| TN2014000434A1 (en) | St2 antigen binding proteins | |
| MX384026B (es) | Terapeuticos de anticuerpo que se unen a ctla4. | |
| HK1250513A1 (zh) | 抗ox40抗体及其使用方法 | |
| NZ626610A (en) | Antibodies that bind csf1r | |
| EA201200549A1 (ru) | Dll4-связывающие молекулы | |
| EA201300311A1 (ru) | Vegf-связывающие молекулы | |
| BR112012024713A2 (pt) | "anticorpo humanizado, anticorpo monoclonal humanizado ou fragmento de anticorpo, seus usos, polinucleotídeo isolado, e composição farmacêutica" | |
| WO2015108998A3 (en) | Cartilage targeting agents and their use | |
| JP2016525516A5 (enExample) | ||
| NZ602166A (en) | Antibodies to il-6 and use thereof | |
| BR112012028920A2 (pt) | formulações de anticorpo de alta concentração | |
| WO2015069794A3 (en) | Novel anti-claudin antibodies and methods of use | |
| EP4311558A3 (en) | Antibodies that bind il-23 | |
| WO2015089449A3 (en) | Novel anti-dpep3 antibodies and methods of use | |
| HRP20221490T1 (hr) | Poboljšanje antitumorskog odgovora t stanice | |
| MX2019010458A (es) | Anticuerpos anti-gitr y metodos de uso de los mismos. | |
| EA201401065A1 (ru) | Ang2-связывающие молекулы |